Brainstorm Cell Therapeutics Inc
NASDAQ:BCLI
BCLI's latest stock split occurred on Oct 1, 2024
The company executed a 1-for-15 stock split, meaning that for every 15 shares held, investors received 1 new share.
Before the split, BCLI traded at 0.2303 per share. Afterward, the share price was about 3.25.
The adjusted shares began trading on Oct 1, 2024. This was BCLI's 4th stock split, following the previous one in Sep 16, 2014.
Global
Stock Splits Monitor
| Date | Company | Split | Pre-Split Price | Post-Split Price | |
|---|---|---|---|---|---|
|
Mar 6, 2026
|
|
Silver Touch Technologies Ltd
NSE:SILVERTUC
|
2-for-1
x2
|
134.59 134.59 INR | 141.3 141.3 INR |
|
Mar 6, 2026
|
Y
|
Yasuhara Chemical Co Ltd
TSE:4957
|
1-for-1186560
/1186560
|
1374 1374 JPY | N/A |
|
Mar 6, 2026
|
|
Kapston Services Ltd
NSE:KAPSTON
|
3-for-2
x1.5
|
397.6 265.07 INR | 278.3 278.3 INR |
|
Mar 6, 2026
|
C
|
Cistro Telelink Ltd
BSE:531775
|
6-for-10
/1.6666666666667
|
1.7833 1.7833 INR | N/A |
|
Mar 5, 2026
|
|
Glacier Lake Resources Inc
OTC:GLIIF
|
1-for-2
/2
|
0.0063 0.015 USD | N/A |
SILVERTUC
KAPSTON
GLIIF
Brainstorm Cell Therapeutics Inc
Glance View
Brainstorm Cell Therapeutics, Inc. operates as a biotechnology company, which develops and commercializes adult stem cell therapeutic products. The company is headquartered in New York City, New York and currently employs 43 full-time employees. The company went IPO on 2003-05-28. The firm is focused on the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases, including Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Progressive Multiple Sclerosis (PMS), Alzheimer's disease (AD), and other neurodegenerative diseases. NurOwn, its cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells (MSCs) to secrete high levels of neurotrophic factors (NTFs), modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival and improve neurological function. NurOwn has completed its phase III ALS and phase II PMS clinical trials. Its wholly owned subsidiary, BrainStorm Cell Therapeutics Ltd. holds the rights to commercialize its NurOwn technology. Its other subsidiaries include Advanced Cell Therapies Ltd., and two others.
